Upcoming events – Fibroid data for Obseva, as Inventiva turns to Nash
Phase III data for Obseva's uterine fibroid project linzagolix need to prove its safety, while Inventiva tests its pan-PPAR agonist lanifibranor in Nash.
Upcoming events – Obseva's first fibroid foray and Newron's test in Retts
Obseva awaits data that could make linzagolix third to market, while Newron looks for a starring role in Retts.
Upcoming events – pivotal readouts for Intra-Cellular and Myovant
Intra-Cellular looks to shore up lumateperone, while Myovant wants to take on Abbvie on its own turf.
Bayer puts the brakes on vilaprisan trials following safety concerns
The decision to halt trials for the uterine fibroid product marks another setback in an area where there are few suitable solutions for patients.
Esmya rejection hits Allergan's streamlining
A US FDA complete response letter has dealt Allergan’s hopes of finding a buyer for its women’s health unit a serious blow.
First-quarter floats see haves pulling away from the have-nots
Demand for new issues remains sluggish - only eight private biotechs managed to pull off an IPO in the first quarter of 2017.
